Home / Intelligence / Blog / Verily to Acquire SignalPath, Expanding the Company’s Clinical Research Capabilities
Published August 30, 2021
Verily recently announced its first major acquisition, a software platform known as SignalPath. SignalPath’s flagship software, TrialPath, digitizes and modulates individual protocols in a clinical trial, from budgeting to tracking point-of-care communication. The acquisition would fold SignalPath into Baseline, Verily’s clinical research platform designed to improve clinical trial execution, help research manage their clinical trials, and explore flexible study options for decentralized and hybrids trials as well as novel ways to capture real-world data (i.e., generated by novel sensors and biomarkers).
While many details of the agreement were not disclosed, including the financial terms, this deal could “set a new standard for clinical studies and evidence generation,” according to Amy Abernethy, MD, PhD, a former principal deputy commissioner at the FDA and current President of Clinical Studies Platforms at Verily. With a tech giant backing and a growing pipeline of digital technologies, including a virtual clinic that provides online care and coaching for chronic conditions, Verily can now use a new system to accelerate its research and trial processes, to quickly establish its presence in the DTx.
Written by Crystal Zhao and Kate Watkins
Related Intelligence
Case Studies
Optimizing HCP Call Planning with a Best‑in‑Class AIML Engine
The Situation Mid-Size Pharma, High-Potential HCP Identification Trinity’s Solution A digitally-integrated, AI-enabled ecosystem powering rep effectiveness and personalized HCP engagement Trinity AI assessed the client’s technology ecosystem and existing targeting engine to scope the context and needs for a more efficient solution. Trinity redesigned an AI-driven call plan engine to identify high-potential HCP targets in […]
Read More
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More